Navigate Side Effects: From nausea to constipation, GLP-1s come with side effects that directly impact nutrition
Clinical trials with semaglutide have demonstrated significant potential to treat diseases of the brain, liver, heart, vascular system (veins and arteries), lungs, bones, skin, and kidneys [1,4], and this class of drugs also shows promise for treating arthritis [1,5]
Furthermore, research shows that MT-II mediates energy expenditure and appetite regulation through MC3R and MC4R activation via PMOC signaling
During the first month of the trial, most events coincided with a rapid and massive drop in HbA1c in dysregulated patients with pre-existing retinopathy
This was not just observed in animal models
Front Endocrinol (Lausanne) 12:721135